Opioid detox for Delray Beach — fentanyl-era protocols, buprenorphine done right.

For Delray Beach residents, RECO Island is not a facility across the state — it is 140 NE 4th Avenue, one block off Atlantic Avenue, minutes from Pineapple Grove and the Beach District. Physician-led opioid detox uses COWS-guided buprenorphine induction with fentanyl-era protocols (including micro-induction where indicated), 24/7 nursing, and same-day admission. Detox transitions directly into RECO Island's residential program under the same medical team — no waitlists, no third-party handoffs, no discharge gap. Every client leaves with a naloxone prescription and an active MAT plan.

RECO Island’s medical detox and residential campus sits at 140 NE 4th Avenue in Delray Beach — one block off Atlantic Avenue, a five-minute walk from the ocean. For residents of Pineapple Grove, Lake Ida, Tropic Isle, the Beach District, or Osceola Park, opioid detox does not require leaving town. Admission is same-day when clinically appropriate, the census is intentionally small, and the transition from acute withdrawal into residential treatment happens under one roof and one medical team.

Opioid withdrawal in the fentanyl era

Fentanyl and its analogs — carfentanil, acetylfentanyl, and increasingly xylazine adulterants — have rewritten opioid withdrawal management. Withdrawal in fentanyl-exposed patients emerges faster, hits harder, and follows a less predictable timeline than the heroin or oxycodone withdrawal that older detox protocols were built around. Because fentanyl is highly lipophilic and sequestered in adipose tissue, elimination is prolonged and uneven; a patient can appear to be clearing the drug for 48-72 hours only to re-experience withdrawal as tissue stores redistribute.

Buprenorphine induction — historically initiated at 12-24 hours of moderate withdrawal — now frequently requires longer intervals or micro-induction protocols to avoid precipitated withdrawal in fentanyl-exposed patients. Opioid detox at RECO Island is COWS-guided, physician-managed, and staffed with 24/7 nursing across the entire induction window. Xylazine co-exposure — now widespread in the street opioid supply and associated with prolonged sedation and characteristic necrotic wounds — is screened for at admission and managed with separate wound care and sedation protocols.

COWS-guided buprenorphine induction

The Clinical Opiate Withdrawal Scale (COWS) scores eleven symptom domains: resting pulse, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, GI upset, tremor, yawning, anxiety or irritability, and gooseflesh skin. Scores below 5 indicate minimal withdrawal; 5-12 mild; 13-24 moderate; 25-36 moderately severe; above 36 severe. Standard buprenorphine induction begins once COWS crosses the moderate threshold — generally 11-13 or higher — with a starting dose of 2-4 mg sublingual, titrated over the first 24 hours to a clinically effective dose in the 8-16 mg range.

For fentanyl-exposed patients that standard is frequently modified. Low-dose or micro-induction protocols — starting at 0.5 mg every few hours and up-titrating slowly while the patient still has residual full agonist on board — allow buprenorphine to establish itself on the mu receptor without triggering precipitated withdrawal. Comfort medications support the induction throughout: clonidine 0.1-0.2 mg for autonomic hyperactivity, loperamide for diarrhea, ondansetron for nausea, hydroxyzine for anxiety and sleep, and short courses of methocarbamol or cyclobenzaprine for myalgia.

Buprenorphine, methadone, or naltrexone — the MAT decision

Post-detox medication-assisted treatment for opioid use disorder has three evidence-supported options, and choosing among them is the single highest-leverage decision made during the detox stay. Buprenorphine is a partial mu agonist with a ceiling effect on respiratory depression, a favorable overdose safety profile, and office-based prescribing under MAT Act rules. Methadone is a full mu agonist with the strongest retention and mortality-reduction data in the literature, but is dispensed only through licensed opioid treatment programs. Extended-release naltrexone (Vivitrol) is a mu antagonist administered as a monthly intramuscular injection; it requires a 7-10 day opioid-free period before initiation to avoid precipitated withdrawal.

The decision is made collaboratively with the client during the detox stay, not imposed on discharge day. Prior response to each agent, occupational constraints (some safety-sensitive professions restrict scheduled medications), pregnancy status, hepatic function, and access to a continuing prescriber in the client’s home region all factor into the recommendation. For Delray Beach clients transitioning directly into RECO Island’s residential program, buprenorphine and naltrexone are both continued in-house; methadone is coordinated with a local opioid treatment program when clinically indicated.

Naloxone education and the post-detox safety net

Every RECO Island opioid detox client — and, where possible, a family member or partner — receives naloxone education and a take-home naloxone prescription at discharge. This is not optional programming. The two-to-four weeks following detox is the highest-mortality window in opioid use disorder: tolerance has dropped substantially while return-to-use risk remains real, and a dose that was tolerated pre-detox can be fatal post-detox.

Intranasal naloxone kits (4 mg formulation), overdose recognition training, and clear instructions on when to call 911 are covered before discharge, not after. Harm reduction counseling names the tolerance-loss window explicitly rather than talking around it. MAT continuation — buprenorphine or naltrexone — is the single most effective intervention for reducing post-detox overdose mortality, and continuity of that prescription from detox through residential and into aftercare is treated as a clinical hand-off, not a paperwork task.

What to expect at admission from Delray Beach

Admission from anywhere in Delray Beach is same-day when clinically appropriate. Intake begins with a full history and physical, urine drug screen, comprehensive metabolic panel, CBC, hepatitis and HIV screening, and a psychiatric assessment covering PHQ-9 for depression, GAD-7 for anxiety, and PC-PTSD-5 for trauma. Withdrawal is scored by COWS on arrival and every 2-4 hours during induction; ASAM Criteria dimensions — acute intoxication and withdrawal potential, biomedical conditions, emotional/behavioral/cognitive, readiness to change, relapse potential, and recovery environment — drive level-of-care placement.

A private room, 24/7 nursing observation, and physician evaluation within the first 24 hours are standard. Medically supervised opioid detox typically runs 5-10 days depending on induction trajectory and any co-occurring alcohol, benzodiazepine, or stimulant withdrawal — polysubstance use is the rule, not the exception, and CIWA-Ar scoring or a supervised benzodiazepine taper may run in parallel. Clients transition directly into residential without a discharge gap, and evidence-based psychotherapy — CBT, DBT skills training, motivational interviewing, and trauma-focused work when clinically indicated — begins during the detox stay as soon as the client is stable enough to engage.

Insurance and admissions from Delray Beach

RECO Island is in-network or accepts single-case agreements with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield plans. Under the Mental Health Parity and Addiction Equity Act, commercial coverage for medically supervised detox and residential SUD care is a federal requirement, and admissions runs a real-time benefits verification at first contact — no surprise bills after admission. For Delray Beach residents, the drive to 140 NE 4th Avenue is effectively zero; most clients are on campus within 15-20 minutes of the initial call.

Serving residents of: Pineapple Grove, Lake Ida, Tropic Isle, Beach District, Osceola Park.